BioCryst Pharmaceuticals
BCRX
#5073
Rank
ยฃ1.19 B
Marketcap
ยฃ5.69
Share price
-3.07%
Change (1 day)
-4.62%
Change (1 year)

Revenue for BioCryst Pharmaceuticals (BCRX)

Revenue in 2025 (TTM): ยฃ0.45 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's current revenue (TTM ) is ยฃ0.44 Billion. In 2024 the company made a revenue of ยฃ0.35 Billion an increase over the revenue in the year 2023 that were of ยฃ0.26 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for BioCryst Pharmaceuticals from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ0.45 B26.68%
2024 ยฃ0.35 B38.07%
2023 ยฃ0.26 B16.2%
2022 ยฃ0.22 B92.26%
2021 ยฃ0.11 B791.03%
2020 ยฃ13.06 M-64.91%
2019 ยฃ37.24 M128.89%
2018 ยฃ16.27 M-12.69%
2017 ยฃ18.63 M-12.74%
2016 ยฃ21.35 M-34.41%
2015 ยฃ32.56 M272.57%
2014 ยฃ8.74 M-16.81%
2013 ยฃ10.5 M-35.41%
2012 ยฃ16.26 M28.72%
2011 ยฃ12.63 M-68.73%
2010 ยฃ40.41 M-12.33%
2009 ยฃ46.09 M19.44%
2008 ยฃ38.59 M7.62%
2007 ยฃ35.85 M1030.89%
2006 ยฃ3.17 M3500.52%
2005 ยฃ0.08 M1799.45%
2004 ยฃ0 M-99.49%
2003 ยฃ0.91 M-17.46%
2002 ยฃ1.1 M-85.62%
2001 ยฃ7.69 M907.86%
2000 ยฃ0.76 M-54.19%
1999 ยฃ1.66 M-58.01%
1998 ยฃ3.96 M443.35%
1997 ยฃ0.73 M-51.89%
1996 ยฃ1.51 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Repligen
RGEN
ยฃ0.53 B 18.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
ยฃ1.81 B 302.41%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
ยฃ0.76 B 70.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
ยฃ21.81 B 4,749.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
ยฃ1.95 M-99.57%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
ยฃ31.76 B 6,960.96%๐Ÿ‡ฌ๐Ÿ‡ง UK
Emergent BioSolutions
EBS
ยฃ0.56 B 25.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA